The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Abstract
Bisphosphonate drugs inhibit osteoclastic bone resorption and are widely used to treat skeletal complications in patients with tumor-induced osteolysis. We now show that zoledronic acid, a new generation bisphosphonate with a heterocyclic imidazole substituent, is also a potent inhibitor of angiogenesis. In vitro, zoledronic acid inhibits proliferation of human endothelial cells stimulated with fetal calf serum, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (IC(50) values 4.1, 4.2, and 6.9 microM, respectively), and modulates endothelial cell adhesion and migration. In cultured aortic rings and in the chicken egg chorioallantoic membrane assay, zoledronic acid reduces vessel sprouting. When administered systemically to mice, zoledronic acid potently inhibits the angiogenesis induced by subcutaneous implants impregnated with bFGF [ED(50), 3 microg/kg (7.5 nmol/kg) s.c.]. These findings indicate that zoledronic acid has marked antiangiogenic properties that could augment its efficacy in the treatment of malignant bone disease and extend its potential clinical use to other diseases with an angiogenic component.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“these agents have also been shown to suppress the proliferation, adhesion, migration, and survival of endothelial cells in vitro (147, 148) while inducing endothelial cell apoptosis in vivo (149).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [147]
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Asahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M., Magner, M., & Isner, J. M. (1999) · Circulation Research · doi:10.1161/01.res.85.3.221 · Cited by 3,263
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,109
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D., Mundy, G. R., & Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,039
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 844
Self-citationReduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I., Solomayer, E., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D. R., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Montesano, R., Orci, L., & VASSALLI, P. (1983) · The Journal of Cell Biology · doi:10.1083/jcb.97.5.1648 · Cited by 647
Berenson, J. R., Lichtenstein, A. K., Porter, L., Dimopoulos, M. A., Bordoni, R. E., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 645
Hortobágyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D. W., Sinoff, C., Wheeler, H. T., Simeone, J. F., Seaman, J. J., Knight, R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 630
Bisphosphonates induce apoptosis in human breast cancer cell lines
Senaratne, S. G., Pirianov, G., Mansi, J., Arnett, T. R., & Langrish, V. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1131 · Cited by 428
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 376
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F. H., Delmas, P. D., & Clézardin, P. (1997) · PubMed · Cited by 343
Saarto, T., BLOMQVIST, C. P., Virkkunen, P. J., & Elomaa, I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.10 · Cited by 337
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
Vascular Progenitors From Biology to Treatment
Luttun, A. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00152-9 · Cited by 193
Peyruchaud, O., Winding, B., Pécheur, I., Serre, C., Delmas, P. D., & Clézardin, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.11.2027 · Cited by 175
Bone Sialoprotein Mediates Human Endothelial Cell Attachment and Migration and Promotes Angiogenesis
Bellahcène, A., Bonjean, K., Fohr, B., Fedarko, N. S., Robey, F. A., Young, M. F., Fisher, L. W., & Castronovo, V. (2000) · Circulation Research · doi:10.1161/01.res.86.8.885 · Cited by 127
Self-citationSuperactivation of integrin αvβ3 by low antagonist concentrations
Legler, D. F., Wiedle, G., Ross, F. P., & Imhof, B. A. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.8.1545 · Cited by 112
Zimolo, Z., Wesolowski, G. A., & Rodan, G. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118283 · Cited by 110
Walker, K. M., Medhurst, S. J., Kidd, B. L., Glatt, M., Bowes, M., Patel, S., McNair, K., Kesingland, A., Green, J., Chan, O., et al. (2002) · Pain · doi:10.1016/s0304-3959(02)00040-4 · Cited by 96
Self-citationAlendronate Reduces Adhesion of Human Osteoclast-like Cells to Bone and Bone Protein-Coated Surfaces
Colucci, S. C., Minielli, V., Zambonin, G., Cirulli, N., Mori, G., Serra, M., Patella, V., Zallone, A. Z., & Grano, M. (1998) · Calcified Tissue International · doi:10.1007/s002239900519 · Cited by 93
Muehleman, C., Green, J. M., Williams, J. M., Kuettner, K. E., Thonar, E. J.-M. A., & Sumner, D. R. (2002) · Osteoarthritis and Cartilage · doi:10.1053/joca.2001.0506 · Cited by 81
Self-citationBisphosphonates in the Treatment of Malignant Bone Disease
Berenson, J. R., & Lipton, A. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.237 · Cited by 65
Bisphosphonates: Mechanisms of Action and Clinical Use in Osteoporosis - An Update
Fleisch, H. A. (1997) · Hormone and Metabolic Research · doi:10.1055/s-2007-979008 · Cited by 61
Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis.
Podworny, N. V., Kandel, R. A., Renlund, R., & Grynpas, M. D. (1999) · PubMed · Cited by 49
ANGIOGENESIS IN THE huPBL-SCID MODEL OF HUMAN TRANSPLANT REJECTION1
Moulton, K. S., Melder, R. J., Dharnidharka, V. R., Hardin-Young, J., Jain, R. K., & Briscoe, D. M. (1999) · Transplantation · doi:10.1097/00007890-199906270-00020 · Cited by 44
Bisphosphonates - Mechanisms of Action in Multiple Myeloma
Rogers, M. J. (2000) · Acta Oncologica · doi:10.1080/028418600750063587 · Cited by 20
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Advances in organ biology · doi:10.1016/s1569-2590(08)60154-8 · Cited by 9
Croucher, P. I., Hijzen, A., Shipman, C. M., Perry, M., Lippitt, J. M., Green, J., Camp, B. V., & Vanderkerken, K. (2001) · VUBIR (Vrije Universiteit Brussel) · Cited by 6
Self-citation
Flagged first, then by citations
1 of the 33 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Boissier, 2020, Zoledronic acid inhibits in vivo experimental angiogenesis (abstract B3)., Bone, 30, 38S
- Bonjean, 2002, Zoledronic acid inhibits human endothelial cell adhesion to vitronectin and selectively alters the expression of extracellular matrix cell surface receptors (abstract B4)., Bone, 30, 38S
Cited by
Sorted by citations
Ruggiero, S. L., Dodson, T. B., Fantasia, J. E., Goodday, R. H. B., Aghaloo, T. L., Mehrotra, B., & O’Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,975
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,299
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,034
Marx, R. E., Sawatari, Y., Fortin, M., & Broumand, V. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.07.010 · Cited by 1,635
Metadata
- Authors
- Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R.
- Affiliations
- Novartis (Switzerland) (CH)
- University of Liège (BE)
- ORCID
- Bellahcène, Akeila
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 302
- Issue
- 3
- Pages
- 1055-1061
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2144860907
- Cited by
- 854
- References
- 33
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 14 · 2023: 20 · 2022: 17 · 2021: 18 · 2020: 22 · 2019: 34 · 2018: 23 · 2017: 20 · 2016: 24 · 2015: 38 · 2014: 46 · 2013: 44 · 2012: 36
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- zoledronic acid, bisphosphonates, antiangiogenic activity, angiogenesis inhibition, endothelial cell proliferation, basic fibroblast growth factor, vascular endothelial growth factor, endothelial cell adhesion, endothelial cell migration, tumor-induced osteolysis, malignant bone disease, chorioallantoic membrane assay
- MeSH terms
- Zoledronic Acid, Pamidronate, Cell Adhesion, Cell Cycle, Cell Movement, Cells, Cultured, Chemotaxis, Chorion, Diphosphonates, Endothelium, Vascular, Growth Substances, Humans, Imidazoles, Lymphokines, Muscle, Smooth, Vascular, Fibroblast Growth Factor 2, Endothelial Growth Factors, Apoptosis, Image Cytometry, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
